Akamatsu, H., Murakami, E., Oyanagi, J., Shibaki, R., Kaki, T., Takase, E., . . . Yamamoto, N. (2019). Immune‐Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non‐Small Cell Lung Cancer. Oncologist.
Chicago Stili AlıntıAkamatsu, Hiroaki, et al. "Immune‐Related Adverse Events By Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders With Advanced Non‐Small Cell Lung Cancer." Oncologist 2019.
MLA AlıntıAkamatsu, Hiroaki, et al. "Immune‐Related Adverse Events By Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders With Advanced Non‐Small Cell Lung Cancer." Oncologist 2019.
Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..